Golgicide A

Golgicide A

SCHEMBL17167481

Fc1cc(F)c2c(c1)[C@@H]1C=CC[C@@H]1C(c1cccnc1)N2

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 4/20 0.45
GAA P10253 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
MCL1 Q07820 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PTPN1 P18031 1/20 0.43
POLB P06746 4/20 0.39
PKM P14618 1/20 0.39
RECQL P46063 1/20 0.39
PTPN7 P35236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Golgicide A SCHEMBL29431758 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL29374617 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL29893179 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL29519829 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL15678653 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL29384501 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
Golgicide A SCHEMBL8075106 1.00 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7899991 0.77 CHRNB2 (0.35) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL16168697 0.74 MAPT (0.54) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL10022355 0.72 MAPT (0.52) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540356-B2 Compounds having a protective activity against toxins with intracellular activity COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-01-10 US disclosed
US-9540356-B2 Compounds having a protective activity against toxins with intracellular activity COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-01-10 US disclosed
US-20150291568-A1 NEW COMPOUNDS HAVING A PROTECTIVE ACTIVITY AGAINST TOXINS WITH INTRACELLULAR ACTIVITY COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-10-15 US disclosed
US-20150291568-A1 NEW COMPOUNDS HAVING A PROTECTIVE ACTIVITY AGAINST TOXINS WITH INTRACELLULAR ACTIVITY COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291568-A1 NEW COMPOUNDS HAVING A PROTECTIVE ACTIVITY AGAINST TOXINS WITH INTRACELLULAR ACTIVITY SLC47A2, SLC47A1, CTSA MAPT 2666/4885MEN1 3445/4885KMT2A 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.